Gene Expression Significance in Personalized Medicine of Non-small Cell Lung Cancer and Gene Expression Analyzing Platforms

Title: Gene Expression Significance in Personalized Medicine of Non-small Cell Lung Cancer and Gene Expression Analyzing Platforms

Volume: 12 Issue: 5

Author(s): Li Zhang, Huiyi Yang and Jiasen Xu

Affiliation:

Keywords: bDNA, gene expression, immunohistochemistry, predictive biomarkers, quantitative assays, RT-PCR, carcinoma, mitosis, DNA synthesis, reverse-transcription quantitative PCR (RT-qPCR)

Abstract: The association between gene expression and clinical characteristics of non-small cell lung cancer (NSCLC) are uncovered. These genes are critical elements in carcinoma physiological processes, including DNA synthesis, DNA repair and mitosis. Genes such as ERCC1, RRM1, TYMS, TUBB3 and STMN1 are predictive biomarker candidates for chemotherapy sensitivity in patients with NSCLC. Suitable gene expression analyzing technology is key factor for the personalize medicine to become a reality. This mini-review will describe and discuss critically on most currently widely used gene expression analyzing technologies, involving immunohistochemistry (IHC), reverse-transcription quantitative PCR (RT-qPCR) and branch-DNA technology (bDNA).

Cite this article as:

Zhang Li, Yang Huiyi and Xu Jiasen, Gene Expression Significance in Personalized Medicine of Non-small Cell Lung Cancer and Gene Expression Analyzing Platforms, Current Drug Metabolism 2011; 12 (5) . https://dx.doi.org/10.2174/138920011795495303